BTLA and Autoimmunity: However, given BTLA’s role in maintaining immune homeostasis, systemic blockade may carry risks of hyperinflammation or autoimmunity, highlighting the need for selective targeting strategies—such as bispecific antibodies that preferentially block BTLA in the TME or cell-specific delivery systems [119,120].